Xcout IntelSign inSubscribe

Gilgamesh Pharma Inc.

BiotechnologyNew York, NY, United States

Gilgamesh Pharma Inc. is a clinical-stage neuroscience company that develops novel chemical entities to treat psychiatric diseases, aiming to move beyond symptom management toward rapid-acting and durable therapies. The company utilizes an AI-powered discovery platform and medicinal chemistry to create precision therapies targeting conditions such as depression, anxiety, addiction, and schizophrenia.

Subscribe to see Gilgamesh Pharma Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Gilgamesh Pharma Inc. at a glance

Gilgamesh Pharma Inc. is a biotechnology company headquartered in New York, United States. It has raised at least $87M across the 2 funding rounds on record. Its most recent funding round raised $60M in January 2026. Xcout tracks 7 named people at Gilgamesh Pharma Inc., including Jonathan Sporn (CEO).

As of 16 November 2026. Source: Xcout Intel.

Industry
Biotechnology
Headquarters
New York, NY, United States
Raised, rounds on record
$87M

Gilgamesh Pharma Inc. leadership

  • Jonathan SpornCEO
  • Andrew KruegelExecutive Officer
  • Jonathan SpornExecutive Officer
  • Amy KruseDirector
  • Phil SkolnickDirector
  • Robert BermanDirector

1 more named person on record for Gilgamesh Pharma Inc., with roles, board committees and tenure — see the full roster →

Gilgamesh Pharma Inc. funding rounds

At least $87M raised across the 2 rounds on record. Every round on record:

DateRoundAmountInvestors
SEC Form D filing$60M—
Series A$27M—

Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →

Gilgamesh Pharma Inc. competitors

A few of Gilgamesh Pharma Inc.'s closest competitors — see the full list of competitors and alternatives →

Alto Neuroscience, Inc.ANRO · BiotechMountain View, CA, United States
74% matchPublic

Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.

Market cap$1.2B
Employees76
Alto Neuroscience, Inc. competitors & alternatives →

Get Gilgamesh Pharma Inc.'s news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Something wrong or missing about Gilgamesh Pharma Inc.? Suggest a correction · Work at Gilgamesh Pharma Inc.? Claim this profile

Is this your company? Add the Xcout Intel badge to your website

Free, for any company on Xcout Intel. It links visitors to this profile.

Gilgamesh Pharma Inc. on Xcout Intel

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Gilgamesh Pharma Inc. — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Gilgamesh Pharma Inc. in Xcout Intel

  • 7 named people with titles, LinkedIn and board committees
  • 2 funding rounds with the investors in each, and who they co-invest with
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →